NTRR – New Federal Bill Marks Major Turning Point in U.S. Medical Cannabis Market

TAMPA, Fla.--()--The recent medical cannabis reform bill introduced to the Senate signals a grand first step toward repealing federal prosecution of medical cannabis, potentially generating huge new opportunities for Neutra Corp. (OTCBB:NTRR) in the booming medical cannabis business.

The bill, introduced by Senators Rand Paul (R-KY), Kirsten Gillibrand (D-NY) and Corey Brooker (D-NJ), seeks to end federal prosecution of medical cannabis in the 23 states where it is available, and re-classify cannabis as a Schedule II narcotic under the Controlled Substances Act, effectively recognizing the plant’s medicinal properties.

If passed, the legislation is sure to broaden the market for products and services in the soaring medical cannabis industry, sales of which grew to $2.7 billion in 2014.

“Ending the federal ban on medical cannabis would be great step forward,” said NTRR CEO Chris Brown. “It would undoubtedly help create a larger base of consumers who can access our cannabis products and services without fear of the federal government stepping in to prosecute. We support the new bill and hope the American public does the same.”

Along with supporting the new bill, NTRR continues to broaden its reach and earnings potential in the medical cannabis market, the fastest-growing industry in the U.S. The company’s recent trip to CannaCon exposed a new audience to its goods and services. Plans for innovative products, such as a libido-enhancing disposable cannabis inhaler and expansion of its environmentally friendly antimicrobial surface protector are currently in development.

These services position NTRR as a major player in the medical cannabis industry and set the standard for the nation’s evolving acceptance of cannabis reform.

About Neutra Corp.

Neutra Corp. is a healthy lifestyle company that specializes in the development and marketing of natural wellness solutions, including cannabis-related products. By providing a variety of new technologies designed to ensure safer, more reliable access to cannabis in approved markets, Neutra Corp. plans to compete alongside GW Pharmaceuticals (OTCBB:GWPRF), INSYS Therapeutics, Inc. (NASDAQ:INSY), and ENDEXX Corp. (OTCBB:EDXC), delivering technological advancements in the cultivation and processing of cannabis in approved markets. For investing information and performance data, please visit www.neutracorp.com.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone’s past success, either financial or strategic, is no guarantee of success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.

Contacts

Neutra Corp.
Chris Brown, 813-367-2041
President and CEO
info@neutracorp.com

Release Summary

Federal medical cannabis reform bill marks turning point for U.S. medical cannabis market.

Contacts

Neutra Corp.
Chris Brown, 813-367-2041
President and CEO
info@neutracorp.com